EU approves Sanofi drug for chronic lung disease
"Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the EU," Sanofi said in a statement.
PREMIUM Health
Blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (Courtesy Phots)
By NewVision Reporter
Journalists @NewVision
_______________
The European Union has approved Sanofi's blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (COPD), the French pharmaceutical giant said on Wednesday.